ghk cu compound GHK-Cu Topical Serum: Benefits, Mechanism & Research Guide GHK-CU – Research Peptide |

Levosalbutamol consists only of the R-enantiomer

International scheduling Australia's Therapeutic Goods Administration (interim decision, April 2024) and New Zealand's Medsafe (Medicines Classification Committee, June 2025) have moved to schedule BPC-157 as a prescription-only medicine, despite its unavailability through legitimate prescription

Improper reconstitution technique is particularly problematic with lyophilized tirzepatide

However, the largest Phase IIb trial involving 536 participants failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading to development termination in 2007

There is no published, peer-reviewed, full-paper randomised human trial with accessible results showing that BPC-157 is effective or safe for any indication